01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Influence of presence/absence of thyroid gland on the cutoff value for thyroglobulin in lymph-node aspiration to detect metastatic papillary thyroid carcinoma
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Case selection
FNA cytology
Measurement of Tg-FNA, serum Tg, and TgAb
Data analysis and statistical analysis
Results
Characteristics of patients and lymph nodes
Metastatic PTC (
n = 111)
|
Lymphadenitis (
n = 50)
|
Metastases from extrathyroidal malignancies (
n = 35)
|
|
---|---|---|---|
Patient’s thyroid conditions
|
|||
No-surgery
|
48 (43.2%)
|
19 (38.0%)
|
33 (94.3%)
|
Partial ablation
|
33 (29.7%)
|
14 (28.0%)
|
2 (5.7%)
|
Total ablation
|
30 (27.0%)
|
17 (34.0%)
|
0 (0%)
|
Size of lymph node
|
|||
≤ 1 cm
|
17 (15.3%)
|
8 (16.0%)
|
0 (0.0%)
|
> 1 cm
|
94 (84.7%)
|
42 (84.0%)
|
35 (100.0%)
|
Characteristics Of lymph node
|
|||
cystic
|
49 (44.1%)
|
3 (6.0%)
|
16 (45.7%)
|
solid
|
62 (55.9%)
|
47 (94.0%)
|
19 (54.3%)
|
Optimal cutoff value for Tg-FNA measurement
Cutoff value at Tg-FNA/serum-Tg ratio > 1.0 for Tg-FNA measurement
Diagnostic ability of FNAC
Cytology diagnosis
|
Final diagnosis
|
||
---|---|---|---|
Metastatic PTC
(
n = 111)
|
Lymphadenitis
(
n = 50)
|
Metastases from extrathyroidal malignancies (
n = 35)
|
|
Benign
|
7
|
49
|
1
|
Atypical
|
5
|
1
|
0
|
Suspicious PTC/Malignance
|
22
|
0
|
6
|
PTC/Malignant
|
77
|
0
|
28
|
Diagnostic performance of FNAC combined with Tg-FNA measurement
Modalities
|
SN
|
SP
|
PPV
|
NPV
|
AC
|
---|---|---|---|---|---|
FNAC
|
89.2% (99/111)
|
100%(85/85)
|
100%(99/99)
|
87.6%(95/107)
|
93.9%(184/196)
|
Tg-FNA
a
|
95.5%(106/111)
|
100%(85/85)
|
100%(106/106)
|
94.4%(85/90)
|
97.4%(191/196)
|
FNAC + Tg-FNA
b
|
99.1%(110/111)
|
100%(85/85)
|
100%(110/110)
|
98.8%(85/86)
|
99.5%(195/196)
|
No.
|
Thyroid condition
|
Lymph-node
characteristics
|
Cytological diagnosis
|
Tg-FNA (ng/mL)
|
Final diagnosis
|
---|---|---|---|---|---|
1
|
Partial ablation
|
Cystic
|
Atypical cells
|
>500
|
Metastatic PTC
|
2
|
Partial ablation
|
Cystic
|
Atypical cells
|
>500
|
Metastatic PTC
|
3
|
Partial ablation
|
Cystic
|
Atypical cells
|
>500
|
Metastatic PTC
|
4
|
Before surgery
|
Cystic
|
Atypical cells
|
259.6
|
Metastatic PTC
|
5
|
Before surgery
|
Cystic
|
Histocytes
|
>500
|
Metastatic PTC
|
6
|
Before surgery
|
Cystic
|
Histocytes
|
>500
|
Metastatic PTC
|
7
|
Total ablation
|
Cystic
|
Histocytes
|
>500
|
Metastatic PTC
|
8
|
Before surgery
|
Cystic
|
Histocytes
|
166.5
|
Metastatic PTC
|
9
|
Total ablation
|
Cystic
|
Histocytes
|
0.642
|
Metastatic carcinoma (squamous carcinoma + a small amount of PTC)
|
10
|
Total ablation
|
Solid
|
Lymphocytes
|
12.80
|
Metastatic PTC
|
11
|
Total ablation
|
Solid
|
Lymphocytes
|
20.12
|
Metastatic PTC
|
12
|
Partial ablation
|
Solid
|
Atypical cells
|
447.40
|
Metastatic PTC
|
Influence of serum TgAb on the diagnostic efficacy of Tg-FNA
Tg-FNA+
a
|
Tg-FNA−
|
|
---|---|---|
Serum TgAb+
b
|
||
Metastatic PTC (
n = 13)
|
12
|
1
|
Lymphadenitis (
n = 0)
|
0
|
0
|
Serum TgAb−
|
||
Metastatic PTC (
n = 46)
|
44
|
2
|
Lymphadenitis (
n = 9)
|
0
|
9
|